Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2026-05-15 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an announcement of the 2025 annual general shareholders’ meeting resolutions for Beda Pharma Co., Ltd., detailing voting results for each proposal, quorum, meeting procedures, and legal opinions. It is not the full annual report or financial statements, but a formal declaration of voting outcomes, matching the definition of a Declaration of Voting Results & Voting Rights Announcement.
2026-05-15 Chinese
国浩律师（杭州）事务所关于贝达药业股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter from Grandall Law Firm regarding Beda Pharmaceutical’s 2025 Annual Shareholders’ Meeting, attesting to the convening, voting procedures, and results. It does not itself contain the report or presentation materials but is a certification/attestation by external counsel. According to the Certification Rule, such letters are classified as Regulatory Filings (RNS).
2026-05-15 Chinese
关于盐酸埃克替尼片IA2高风险-IB期术后辅助治疗适应症药物临床试验申请获得受理的公告
Regulatory Filings Classification · 84% confidence The document is a public announcement by the board of Beda Pharmaceutical Co., Ltd. informing investors that the National Medical Products Administration (NMPA) has accepted their clinical trial application for a new drug indication. There is no financial data, management changes, voting results, or earnings information. This is a general regulatory compliance announcement about a drug trial approval process, which falls under the fallback category of Regulatory Filings (RNS).
2026-05-13 Chinese
2025年年度审计报告
Audit Report / Information Classification · 95% confidence The document is titled “审计报告及财务报表” for the 2025 fiscal year and contains the auditor’s opinion, key audit matters, responsibilities and the complete set of audited financial statements. It does not include narrative sections typical of a full Annual Report (10-K) or MD&A, nor is it merely an announcement. It is a standalone audit report with financial statements, matching the Audit Report / Information category.
2026-04-22 Chinese
2025年度独立董事述职报告（肖佳佳）
Governance Information Classification · 87% confidence The document is titled “2025年度独立董事述职报告” and consists of the independent director’s formal annual performance and governance duties report, including attendance at board and committee meetings, oversight activities, independence confirmations, and key governance matters. This is not a full annual report, earnings release, proxy statement, or management discussion; rather, it is a standalone governance disclosure related to board structure, director responsibilities, and compliance with corporate governance rules. Therefore, it best fits the Governance Information category (CGR).
2026-04-22 Chinese
关于“质量回报双提升”行动方案的进展公告
Regulatory Filings Classification · 80% confidence The document is a Chinese "进展公告" (progress announcement) of an ongoing “quality return double improvement” action plan by a listed pharmaceutical company, outlining pipeline updates, financial metrics, governance changes, and dividend policy. It is not a formal annual or interim report, not an earnings release, nor a financing, M&A, or other specialized filing. It is a general regulatory announcement of company operations and progress, which falls into the fallback “Regulatory Filings” category.
2026-04-22 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.